Latham & Watkins Advises Gate Bioscience on US$65 Million Series B Financing

"Latham & Watkins LLP advised Gate Bioscience on the close of an oversubscribed US$65 million Series B led by Forbion and joined by Eli Lilly. Existing investors included Versant Ventures, Andreessen Horowitz Bio+Health, GV and ARCH Venture Partners. Gate develops small‑molecule medicines to eliminate disease‑causing proteins."

Latham & Watkins LLP represented Gate Bioscience in the Series B financing. Gate Bioscience, a biotechnology company developing a new class of small‑molecule medicines aimed at eliminating disease‑causing proteins at their source, has closed an oversubscribed US$65 million Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company, alongside existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners. Latham & Watkins LLP represented Gate Bioscience with a team composed by: Kathleen Wells, Bay Area partner, Emerging Companies & Growth; associates Christopher Pham and Jack McKay; and Wes Dantzler, who provided assistance.

Latham & Watkins Advises Gate Bioscience on US$65 Million Series B Financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads